Asari Sadaki, Matsumoto Ippei, Toyama Hirochika, Shinzeki Makoto, Goto Tadahiro, Ishida Jun, Ajiki Tetsuo, Fukumoto Takumi, Ku Yonson
Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Surg Today. 2016 May;46(5):583-92. doi: 10.1007/s00595-015-1206-3. Epub 2015 Jun 25.
The therapeutic strategy for borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) has remained unestablished because the preoperative prognostic factors have not been determined.
One hundred eighty-four consecutive PDAC patients who underwent upfront surgery with a curative resection between January 2000 and June 2013 at Kobe University Hospital were retrospectively studied. The PDAC patients were stratified into resectable (R)-PDAC (n = 147) and BR-PDAC patients (n = 37). We evaluated the independent prognostic significance of the neutrophil-lymphocyte ratio (NLR) and the platelet-lymphocyte ratio (PLR) in the BR-PDAC patients.
BR-PDAC patient survival was significantly worse than R-PDAC patient survival (median survival time: 22.1 months vs. 24.3 months; 5-year survival rate 6 vs. 21 %; P = 0.042). The median survival in BR-PDAC patients with a preoperative NLR of >3 (n = 12) was 10.2 months, while that in patients with preoperative NLR of ≤3 (n = 25) was 24.9 months (P = 0.002). Moreover, the median survival in BR-PDAC patients with a preoperative PLR of >225 (n = 8) was 10.2 months, while that in patients with a preoperative PLR of ≤225 (n = 29) was 24.7 months (P = 0.003). Preoperative NLR >3 (HR = 2.980, 95 % CI 1.251-6.920; P = 0.015) and PLR >225 (HR = 3.050, 95 % CI 1.169-7.468; P = 0.024) were independent prognostic factors in BR-PDAC patients.
Higher preoperative NLR and PLR can be independent predictive risk factors in BR-PDAC patients following curative resection.
由于术前预后因素尚未确定,可切除边缘的胰腺导管腺癌(BR-PDAC)的治疗策略仍未确立。
回顾性研究2000年1月至2013年6月在神户大学医院接受根治性切除初次手术的184例连续性PDAC患者。将PDAC患者分为可切除(R)-PDAC组(n = 147)和BR-PDAC组(n = 37)。我们评估了BR-PDAC患者中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)的独立预后意义。
BR-PDAC患者的生存率明显低于R-PDAC患者(中位生存时间:22.1个月对24.3个月;5年生存率6%对21%;P = 0.042)。术前NLR>3的BR-PDAC患者(n = 12)的中位生存期为10.2个月,而术前NLR≤3的患者(n = 25)为24.9个月(P = 0.002)。此外,术前PLR>225的BR-PDAC患者(n = 8)的中位生存期为10.2个月,而术前PLR≤225的患者(n = 29)为24.7个月(P = 0.003)。术前NLR>3(HR = 2.980,95%CI 1.251 - 6.920;P = 0.015)和PLR>225(HR = 3.050,95%CI 1.169 - 7.468;P = 0.024)是BR-PDAC患者的独立预后因素。
较高的术前NLR和PLR可作为BR-PDAC患者根治性切除后的独立预测风险因素。